AFT Pharmaceuticals Ltd Ordinary Shares - Announcements

Add to my watchlist

Healthcare

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

AFT	Distribution notice	PRICE SENSITIVE	120.13KB	Share
AFT	AFT reports record revenue and earnings	PRICE SENSITIVE	173.39KB	Share
AFT	AFT updates operating profit guidance to $23m to $25m	PRICE SENSITIVE	144.72KB	Share
AFT	Maxigesic IV launched in the United States	PRICE SENSITIVE	346.8KB	Share
AFT	AFT Pharma reports growth and global expansion	PRICE SENSITIVE	183.91KB	Share
AFT	AFT welcomes US FDA approval for sale of Maxigesic IV	PRICE SENSITIVE	119.23KB	Share
AFT	AFT declares maiden dividend; record revenue	PRICE SENSITIVE	1.67MB	Share
AFT	Maxigesic Rapid tablets gain US FDA approval	PRICE SENSITIVE	102.55KB	Share
AFT	221124 Interim results FY23H1 App 2 amended	PRICE SENSITIVE	184.12KB	Share
AFT	AFT extends growth investment as sales surge	PRICE SENSITIVE	154.45KB	Share
AFT	US FDA seeks more information on Maxigesic IV(R) application	PRICE SENSITIVE	137KB	Share
AFT	Annual Report revision	PRICE SENSITIVE	7.6MB	Share
AFT	AFT full year results FY2022	PRICE SENSITIVE	187.22KB	Share
AFT	AFT reaffirms guidance and progresses growth plan	PRICE SENSITIVE	225.45KB	Share
AFT	US FDA accepts Maxigesic IV(R) New Drug Application	PRICE SENSITIVE	166.57KB	Share
AFT	MEETING: AFT: ASM Presentation and Chair's address	PRICE SENSITIVE	160.62KB	Share
AFT	FLLYR: AFT: AFT delivers growth amid global disruptions	PRICE SENSITIVE	195.92KB	Share
AFT	GENERAL: AFT: AFT licenses Maxigesic(R) IV in the US	PRICE SENSITIVE	148.85KB	Share
AFT	GENERAL: AFT: AFT updates earnings guidance	PRICE SENSITIVE	126.03KB	Share
AFT	INTERIM: AFT: FINANCIAL RESULTS FOR HALF YEAR ENDED 30 SEPTEMBER 2020	PRICE SENSITIVE	250.06KB	Share
AFT	GENERAL: AFT: AFT welcomes US FDA Complete Response Letter	PRICE SENSITIVE	120.5KB	Share
AFT	MKTUPDTE: AFT: AFT Pharmaceuticals Share Purchase Plan Oversubscribed	PRICE SENSITIVE	113.76KB	Share
AFT	SECISSUE: AFT: Issue of ordinary shares	PRICE SENSITIVE	121.13KB	Share
AFT	OFFER: AFT: AFT announces successful completion of Placement	PRICE SENSITIVE	129.11KB	Share
AFT	OFFER: AFT: AFGT annoucements capital raising to support liquidity	PRICE SENSITIVE	174.91KB	Share
AFT	SECISSUE: AFT: Conversion of redeemable preference shares	PRICE SENSITIVE	113.99KB	Share
AFT	FLLYR: AFT: AFT FY2020 Results annoucement	PRICE SENSITIVE	253.18KB	Share
AFT	AFT finalises refinancing and gives trading update	PRICE SENSITIVE	108.33KB	Share
AFT	Market Trading Update	PRICE SENSITIVE	109.04KB	Share
AFT	AFT on track to refinance CRG term loan facility	PRICE SENSITIVE	106.16KB	Share
AFT	Condensed consolidated interim financial statements	PRICE SENSITIVE	307.69KB	Share
AFT	AFT earnings rise in line with guidance	PRICE SENSITIVE	296.58KB	Share
AFT	AFT to book one-off non-cash gain on Pascomer® assets	PRICE SENSITIVE	117.44KB	Share
AFT	Annual Shareholders Meeting Address and Presentation	PRICE SENSITIVE	3.03MB	Share
AFT	AFT Licensing Agreement for Pascomer® in North America	PRICE SENSITIVE	158.36KB	Share
AFT	FY2019 Annual Report	PRICE SENSITIVE	3.51MB	Share
AFT	AFT Pharmaceuticals establishes new borrowing facilities	PRICE SENSITIVE	120.95KB	Share
AFT	AFT Pharmaceuticals poised for strong earnings growth	PRICE SENSITIVE	157.27KB	Share
AFT	FINANCIAL RESULTS FOR HALF YEAR ENDED 30 SEPTEMBER 2018	PRICE SENSITIVE	224.01KB	Share
AFT	Maxigesic is now licensed in the Russian Federation	PRICE SENSITIVE	50.61KB	Share
AFT	AFT Annual Meeting 2018 Presentation	PRICE SENSITIVE	661.78KB	Share
AFT	Chairman's Address at AFT Annual Meeting	PRICE SENSITIVE	298.42KB	Share
AFT	Annual Report	PRICE SENSITIVE	3.73MB	Share
AFT	Annual Report FY2018	PRICE SENSITIVE	3.73MB	Share
AFT	AFT FY2018 Results Announcement	PRICE SENSITIVE	165.65KB	Share
AFT	AFT Divests Non-Core Products to Focus on Key Products	PRICE SENSITIVE	120.99KB	Share
AFT	FINANCIAL RESULTS FOR HALF YEAR ENDED 30 SEPTEMBER 2017	PRICE SENSITIVE	168.32KB	Share
AFT	Results for announcement to the market App1	PRICE SENSITIVE	107.46KB	Share
AFT	Interim Report FY2018	PRICE SENSITIVE	852.02KB	Share
AFT	FY2018 H1 Update Presentation	PRICE SENSITIVE	2.3MB	Share
AFT	2017 Annual Meeting Presentations	PRICE SENSITIVE	64.39KB	Share
AFT	Issue of Annual Report to security holders	PRICE SENSITIVE	1.78MB	Share
AFT	Share Purchase Plan Opens	PRICE SENSITIVE	98.9KB	Share
AFT	AFT FY2017 Results Announcement	PRICE SENSITIVE	203.17KB	Share
AFT	Maxigesic now licensed in France	PRICE SENSITIVE	47.69KB	Share
AFT	AFT Pharmaceuticals Presentation - Business Update	PRICE SENSITIVE	919.19KB	Share
AFT	RPS SPP Announcement	PRICE SENSITIVE	106.03KB	Share
AFT	Market Update	PRICE SENSITIVE	69.07KB	Share
AFT	AFT Presentation FY2017 1H Year Update - amended	PRICE SENSITIVE	1.09MB	Share
AFT	AFT Half Year Announcement	PRICE SENSITIVE	166.9KB	Share
AFT	AFT Half Year Announcement App I	PRICE SENSITIVE	106.61KB	Share
AFT	AFT Pharmaceuticals Presentation FY2017 1H Year Update	PRICE SENSITIVE	1.09MB	Share
AFT	AFT Interim Report H1 FY17	PRICE SENSITIVE	2.46MB	Share
AFT	AFT Pharmaceuticals Limited – Market Trade Update FY2017 H1	PRICE SENSITIVE	79.59KB	Share

AFT Distribution notice
23/05/24	PRICE SENSITIVE	120.13KB	Share
AFT AFT reports record revenue and earnings
23/05/24	PRICE SENSITIVE	173.39KB	Share
AFT AFT updates operating profit guidance to $23m to $25m
16/02/24	PRICE SENSITIVE	144.72KB	Share
AFT Maxigesic IV launched in the United States
07/02/24	PRICE SENSITIVE	346.8KB	Share
AFT AFT Pharma reports growth and global expansion
23/11/23	PRICE SENSITIVE	183.91KB	Share
AFT AFT welcomes US FDA approval for sale of Maxigesic IV
18/10/23	PRICE SENSITIVE	119.23KB	Share
AFT AFT declares maiden dividend; record revenue
22/05/23	PRICE SENSITIVE	1.67MB	Share
AFT Maxigesic Rapid tablets gain US FDA approval
02/03/23	PRICE SENSITIVE	102.55KB	Share
AFT 221124 Interim results FY23H1 App 2 amended
24/11/22	PRICE SENSITIVE	184.12KB	Share
AFT AFT extends growth investment as sales surge
24/11/22	PRICE SENSITIVE	154.45KB	Share
AFT US FDA seeks more information on Maxigesic IV(R) application
01/07/22	PRICE SENSITIVE	137KB	Share
AFT Annual Report revision
23/05/22	PRICE SENSITIVE	7.6MB	Share
AFT AFT full year results FY2022
23/05/22	PRICE SENSITIVE	187.22KB	Share
AFT AFT reaffirms guidance and progresses growth plan
18/11/21	PRICE SENSITIVE	225.45KB	Share
AFT US FDA accepts Maxigesic IV(R) New Drug Application
01/11/21	PRICE SENSITIVE	166.57KB	Share
AFT MEETING: AFT: ASM Presentation and Chair's address
06/08/21	PRICE SENSITIVE	160.62KB	Share
AFT FLLYR: AFT: AFT delivers growth amid global disruptions
24/05/21	PRICE SENSITIVE	195.92KB	Share
AFT GENERAL: AFT: AFT licenses Maxigesic(R) IV in the US
28/04/21	PRICE SENSITIVE	148.85KB	Share
AFT GENERAL: AFT: AFT updates earnings guidance
01/04/21	PRICE SENSITIVE	126.03KB	Share
AFT INTERIM: AFT: FINANCIAL RESULTS FOR HALF YEAR ENDED 30 SEPTEMBER 2020
19/11/20	PRICE SENSITIVE	250.06KB	Share
AFT GENERAL: AFT: AFT welcomes US FDA Complete Response Letter
09/11/20	PRICE SENSITIVE	120.5KB	Share
AFT MKTUPDTE: AFT: AFT Pharmaceuticals Share Purchase Plan Oversubscribed
01/07/20	PRICE SENSITIVE	113.76KB	Share
AFT SECISSUE: AFT: Issue of ordinary shares
15/06/20	PRICE SENSITIVE	121.13KB	Share
AFT OFFER: AFT: AFT announces successful completion of Placement
11/06/20	PRICE SENSITIVE	129.11KB	Share
AFT OFFER: AFT: AFGT annoucements capital raising to support liquidity
10/06/20	PRICE SENSITIVE	174.91KB	Share
AFT SECISSUE: AFT: Conversion of redeemable preference shares
20/05/20	PRICE SENSITIVE	113.99KB	Share
AFT FLLYR: AFT: AFT FY2020 Results annoucement
20/05/20	PRICE SENSITIVE	253.18KB	Share
AFT AFT finalises refinancing and gives trading update
23/03/20	PRICE SENSITIVE	108.33KB	Share
AFT Market Trading Update
10/03/20	PRICE SENSITIVE	109.04KB	Share
AFT AFT on track to refinance CRG term loan facility
27/02/20	PRICE SENSITIVE	106.16KB	Share
AFT Condensed consolidated interim financial statements
21/11/19	PRICE SENSITIVE	307.69KB	Share
AFT AFT earnings rise in line with guidance
21/11/19	PRICE SENSITIVE	296.58KB	Share
AFT AFT to book one-off non-cash gain on Pascomer® assets
04/11/19	PRICE SENSITIVE	117.44KB	Share
AFT Annual Shareholders Meeting Address and Presentation
02/08/19	PRICE SENSITIVE	3.03MB	Share
AFT AFT Licensing Agreement for Pascomer® in North America
05/07/19	PRICE SENSITIVE	158.36KB	Share
AFT FY2019 Annual Report
22/05/19	PRICE SENSITIVE	3.51MB	Share
AFT AFT Pharmaceuticals establishes new borrowing facilities
22/05/19	PRICE SENSITIVE	120.95KB	Share
AFT AFT Pharmaceuticals poised for strong earnings growth
22/05/19	PRICE SENSITIVE	157.27KB	Share
AFT FINANCIAL RESULTS FOR HALF YEAR ENDED 30 SEPTEMBER 2018
22/11/18	PRICE SENSITIVE	224.01KB	Share
AFT Maxigesic is now licensed in the Russian Federation
28/09/18	PRICE SENSITIVE	50.61KB	Share
AFT AFT Annual Meeting 2018 Presentation
03/08/18	PRICE SENSITIVE	661.78KB	Share
AFT Chairman's Address at AFT Annual Meeting
03/08/18	PRICE SENSITIVE	298.42KB	Share
AFT Annual Report
19/06/18	PRICE SENSITIVE	3.73MB	Share
AFT Annual Report FY2018
15/06/18	PRICE SENSITIVE	3.73MB	Share
AFT AFT FY2018 Results Announcement
23/05/18	PRICE SENSITIVE	165.65KB	Share
AFT AFT Divests Non-Core Products to Focus on Key Products
21/03/18	PRICE SENSITIVE	120.99KB	Share
AFT FINANCIAL RESULTS FOR HALF YEAR ENDED 30 SEPTEMBER 2017
23/11/17	PRICE SENSITIVE	168.32KB	Share
AFT Results for announcement to the market App1
23/11/17	PRICE SENSITIVE	107.46KB	Share
AFT Interim Report FY2018
23/11/17	PRICE SENSITIVE	852.02KB	Share
AFT FY2018 H1 Update Presentation
23/11/17	PRICE SENSITIVE	2.3MB	Share
AFT 2017 Annual Meeting Presentations
04/08/17	PRICE SENSITIVE	64.39KB	Share
AFT Issue of Annual Report to security holders
12/06/17	PRICE SENSITIVE	1.78MB	Share
AFT Share Purchase Plan Opens
24/05/17	PRICE SENSITIVE	98.9KB	Share
AFT AFT FY2017 Results Announcement
24/05/17	PRICE SENSITIVE	203.17KB	Share
AFT Maxigesic now licensed in France
22/05/17	PRICE SENSITIVE	47.69KB	Share
AFT AFT Pharmaceuticals Presentation - Business Update
17/03/17	PRICE SENSITIVE	919.19KB	Share
AFT RPS SPP Announcement
17/03/17	PRICE SENSITIVE	106.03KB	Share
AFT Market Update
17/02/17	PRICE SENSITIVE	69.07KB	Share
AFT AFT Presentation FY2017 1H Year Update - amended
25/11/16	PRICE SENSITIVE	1.09MB	Share
AFT AFT Half Year Announcement
24/11/16	PRICE SENSITIVE	166.9KB	Share
AFT AFT Half Year Announcement App I
24/11/16	PRICE SENSITIVE	106.61KB	Share
AFT AFT Pharmaceuticals Presentation FY2017 1H Year Update
24/11/16	PRICE SENSITIVE	1.09MB	Share
AFT AFT Interim Report H1 FY17
24/11/16	PRICE SENSITIVE	2.46MB	Share
AFT AFT Pharmaceuticals Limited – Market Trade Update FY2017 H1
11/11/16	PRICE SENSITIVE	79.59KB	Share

REFRESH

(20min delay)
Last $2.91		Change -0.230(7.32%)		Mkt cap ! n/a

Open	High	Low	Value	Volume
$3.14	$3.19	$2.91	$155.4K	49.48K

Buyers (Bids)

No.	Vol.	Price($)
0	3257	$2.90

Sellers (Offers)

Price($)	Vol.	No.
$3.12	3889	0

Last trade - 12.59pm 24/05/2024 (20 minute delay)

AFT (NZSX) Chart

AFT Pharmaceuticals Ltd Ordinary Shares - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available